Literature DB >> 33386555

Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis.

Pipit Burasakarn1,2, Ryota Higuchi3, Souya Nunobe4, Shingo Kanaji5, Hidetoshi Eguchi6, Ken-Ichi Okada7, Tsutomu Fujii8, Yuichi Nagakawa9, Kengo Kanetaka10, Hiroharu Yamashita11, Suguru Yamada12, Shinji Kuroda13, Toru Aoyama14, Takahiro Akahori15, Kenji Nakagawa15, Masakazu Yamamoto1, Hiroki Yamaue7, Masayuki Sho15, Yasuhiro Kodera12.   

Abstract

It is well known that surgery is the mainstay treatment for duodenal adenocarcinoma. However, the optimal extent of surgery is still under debate. We aimed to systematically review and perform a meta-analysis of limited resection (LR) and pancreatoduodenectomy for patients with duodenal adenocarcinoma. A systematic electronic database search of the literature was performed using PubMed and the Cochrane Library. All studies comparing LR and pancreatoduodenectomy for patients with duodenal adenocarcinoma were selected. Long-term overall survival was considered as the primary outcome, and perioperative morbidity and mortality as the secondary outcomes. Fifteen studies with a total of 3166 patients were analyzed; 995 and 1498 patients were treated with limited resection and pancreatoduodenectomy, respectively. Eight and 7 studies scored a low and intermediate risk of publication bias, respectively. The LR group had a more favorable result than the pancreatoduodenectomy group in overall morbidity (odd ratio [OR]: 0.33, 95% confidence interval [CI] 0.17-0.65) and postoperative pancreatic fistula (OR: 0.13, 95% CI 0.04-0.43). Mortality (OR: 0.96, 95% CI 0.70-1.33) and overall survival (OR: 0.61, 95% CI 0.33-1.13) were not significantly different between the two groups, although comparison of the two groups stratified by prognostic factors, such as T categories, was not possible due to a lack of detailed data. LR showed long-term outcomes equivalent to those of pancreatoduodenectomy, while the perioperative morbidity rates were lower. LR could be an option for selected duodenal adenocarcinoma patients with appropriate location or depth of invasion, although further studies are required.

Entities:  

Keywords:  Duodenal adenocarcinoma; Duodenal cancer; Limited resection; Pancreatoduodenectomy; Surgery

Year:  2021        PMID: 33386555     DOI: 10.1007/s10147-020-01840-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  56 in total

1.  Primary duodenal adenocarcinoma: a ten-year experience with 79 patients.

Authors:  D M Rose; S N Hochwald; D S Klimstra; M F Brennan
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

2.  The incidence and prognosis of true duodenal carcinomas.

Authors:  T Buchbjerg; C Fristrup; M B Mortensen
Journal:  Surg Oncol       Date:  2015-04-22       Impact factor: 3.279

3.  Improving survival in adenocarcinoma of the duodenum.

Authors:  D R Joesting; R W Beart; J A van Heerden; L H Weiland
Journal:  Am J Surg       Date:  1981-02       Impact factor: 2.565

4.  Clinicopathological characteristics and survival analysis of primary duodenal cancers: a 14-year experience in a tertiary centre in South China.

Authors:  Shenghong Zhang; Yi Cui; Bihui Zhong; Weiwei Xiao; Xiaorong Gong; Kang Chao; Minhu Chen
Journal:  Int J Colorectal Dis       Date:  2010-10-08       Impact factor: 2.571

5.  Surgical treatment of primary duodenal adenocarcinoma.

Authors:  Ji-Xiong Hu; Xiong-Ying Miao; De-Wu Zhong; Wei-Dong Dai; Wei Liu; Wei Hu
Journal:  Hepatogastroenterology       Date:  2006 Nov-Dec

6.  Primary carcinoma of the duodenum.

Authors:  A Alwmark; A Andersson; A Lasson
Journal:  Ann Surg       Date:  1980-01       Impact factor: 12.969

Review 7.  Small Bowel Adenocarcinoma.

Authors:  Thomas Aparicio; Aziz Zaanan; Florence Mary; Pauline Afchain; Sylvain Manfredi; Thomas Ronald Jeffry Evans
Journal:  Gastroenterol Clin North Am       Date:  2016-09       Impact factor: 3.806

8.  Primary adenocarcinoma of the duodenum: management and survival in 67 patients.

Authors:  G Barnes; L Romero; K R Hess; S A Curley
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

9.  Prognostic factors associated with survival in patients with primary duodenal adenocarcinoma.

Authors:  Woo Chul Chung; Chang Nyol Paik; Sung Hoon Jung; Kang-Moon Lee; Sang Woo Kim; U-Im Chang; Jin Mo Yang
Journal:  Korean J Intern Med       Date:  2011-03-02       Impact factor: 2.884

10.  Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Laura L Meijer; Anna J Alberga; Jacob K de Bakker; Hans J van der Vliet; Tessa Y S Le Large; Nicole C T van Grieken; Ralph de Vries; Freek Daams; Barbara M Zonderhuis; Geert Kazemier
Journal:  Ann Surg Oncol       Date:  2018-06-26       Impact factor: 5.344

View more
  4 in total

1.  Segmental resection with partial mesopancreatic and mesojejunal excision (pMME) for duodenal carcinoma of the third or fourth portion.

Authors:  Ryota Ito; Yoshihiro Mise; Yu Takahashi; Yosuke Inoue; Fumihiro Kawano; Haruka Tanaka; Shoichi Irie; Hirofumi Ichida; Ryuji Yoshioka; Akio Saiura
Journal:  Langenbecks Arch Surg       Date:  2022-05-30       Impact factor: 2.895

2.  Pancreas-preserving limited duodenal resection: Minimizing morbidity without compromising oncological adequacy.

Authors:  Ajay Sharma; Anand Nagar; Peeyush Varshney; Maunil Tomar; Shashwat Sarin; Rajendra Prasad Choubey; V K Kapoor
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-05-31

3.  Pancreas-preserving partial duodenectomy for non-ampullary duodenal neoplasms: three case reports.

Authors:  Shunsuke Ishida; Teijiro Hirashita; Yoko Kawano; Hiroki Orimoto; Shota Amano; Masahiro Kawamura; Atsuro Fujinaga; Takahide Kawasaki; Takashi Masuda; Yuichi Endo; Masayuki Ohta; Masafumi Inomata
Journal:  Surg Case Rep       Date:  2022-07-23

4.  Surgical treatment and survival analysis of primary duodenal malignant tumor: a retrospective cohort study.

Authors:  Zhicheng Zhao; Jiehong Zhang; Chuan Li; Tong Liu; Weidong Li
Journal:  J Gastrointest Oncol       Date:  2022-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.